Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®

Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis

(2015) Letizia Leocani et al.   JOURNAL OF NEUROLOGY

Drug-resistant MS spasticity treatment with Sativex®add-on and driving ability

(2014) M. Freidel et al.   ACTA NEUROLOGICA SCANDINAVICA

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Electrophysiological characterisation of motor and sensory tracts in patients with hereditary spastic paraplegia (HSP)

(2013) Kathrin N Karle et al.   Orphanet Journal of Rare Diseases

Measurement and clinical effect of grey matter pathology in multiple sclerosis

(2012) Jeroen JG Geurts et al.   LANCET NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Neuroprotective agents: Cannabinoids

(2011) A.J. Sánchez et al.   CLINICAL IMMUNOLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

FSL

(2011) Mark Jenkinson et al.   NEUROIMAGE

The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration

(2010) Aoife Gowran et al.   CNS Neuroscience & Therapeutics

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Spasticity Mechanisms – for the Clinician

(2010) Angshuman Mukherjee et al.   Frontiers in Neurology

Cannabinoids and experimental models of multiple sclerosis

(2009) Ilona Kubajewska et al.   IMMUNOBIOLOGY

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis

(2009) Diego Centonze et al.   NEUROLOGICAL SCIENCES

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

(2007) G Pryce et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification

(2007) Kegang Hua et al.   NEUROIMAGE